P-1662. Post-Acute Sequelae of COVID-19 and Post-COVID-19 Vaccination Syndrome: A Comparison of Clinical Immune Biomarkers

Abstract Background Post-acute sequelae of COVID-19 (PASC), and post-COVID-19 vaccination syndrome (PVS) present overlapping but distinct clinical challenges. Immunologic biomarker abnormalities have previously been established in PASC but less so in PVS. This study aims to distinguish immunologic biomarker patterns in PASC and PVS.Figure 1Clinical lab abnormality level, as defined by percent of patients with abnormal lab result at anytime (initial visit or follow-up), compared between the long covid positive for MECFS (MECFS), post-vaccination syndrome (PVS), and long covid negative for MECFS (LC) groups and previously reported positivity rates in healthy populations. Histamine: plasma histamine level, Tryptase: plasma tryptase level, IL 2 receptor: interleukin 2 receptor (CD25), IL 10: interleukin 10, IL 13: interleukin 13, TNF-alpha: tumor necrosis factor alpha, CD4+ T Cells: quantitative CD3+/CD4 lymphocytes, CD8+ T Cells: quantitative CD8+ lymphocytes, HSP70: heat shock protein-70 IgG western blot, ACL: quantitative anticardiolipin IgM, Anti U1-RNP: quantitative ribonucleic protein extranuclear antibody IgG. Reference ranges: Histamine: 0-8 mmol/L, Tryptase: